ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · EU licence (European Commission)

Zanidatamab (Ziihera)

Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).

OrphanConditional
CHMP opinion 25 Apr 2025 → EU licence 27 Jun 2025 · Jazz Pharmaceuticals Ireland Limited

Research

Oncology · Clin Cancer Res · 2026-06-01

Combined analysis of 3 early-phase trials in 10 patients with previously treated HER2-positive salivary gland cancer: with zanidatamab monotherapy (n=9), confirmed ORR was 44% and median PFS 10.1 months; related AEs were all grade 1/2.

Meta-analysisn = 10
Lee et al. Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients with Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.